Everolimus: side effect profile and management of toxicities in breast cancer

E Paplomata, A Zelnak, R O'Regan - Breast cancer research and treatment, 2013 - Springer
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR),
which has been approved in combination with exemestane for hormone receptor-positive …
被引用次数：91 相关文章

[引用][C] Everolimus: side effect profile and management of toxicities in breast cancer

E PAPLOMATA, A ZELNAK… - Breast cancer research …, 2013 - pascal-francis.inist.fr
Everolimus: side effect profile and management of toxicities in breast cancer CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …

Everolimus: side effect profile and management of toxicities in breast cancer

E Paplomata, A Zelnak, R O'Regan - Breast Cancer Research and …, 2013 - go.gale.com
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR),
which has been approved in combination with exemestane for hormone receptor-positive …

Everolimus: side effect profile and management of toxicities in breast cancer

E Paplomata, A Zelnak, R O'Regan - Breast Cancer Research and …, 2013 - infona.pl
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR),
which has been approved in combination with exemestane for hormone receptor-positive …

Everolimus: side effect profile and management of toxicities in breast cancer

E Paplomata, A Zelnak… - Breast Cancer Research …, 2013 - search.proquest.com
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR),
which has been approved in combination with exemestane for hormone receptor-positive …

Everolimus: side effect profile and management of toxicities in breast cancer

E Paplomata, A Zelnak… - Breast cancer research …, 2013 - pubmed.ncbi.nlm.nih.gov
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR),
which has been approved in combination with exemestane for hormone receptor-positive …

Everolimus: side effect profile and management of toxicities in breast cancer.

E Paplomata, A Zelnak, R O'Regan - Breast Cancer Research and …, 2013 - europepmc.org
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR),
which has been approved in combination with exemestane for hormone receptor-positive …

[引用][C] Everolimus: side effect profile and management of toxicities in breast cancer

E Paplomata, A Zelnak, R O'Regan - Breast cancer research and treatment, 2013 - Springer

[引用][C] Everolimus: side effect profile and management of toxicities in breast cancer

E PAPLOMATA, A ZELNAK, R O'REGAN - Breast cancer research and …, 2013 - Springer